These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24482441)

  • 1. Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: double-blind randomised placebo-controlled trial.
    Rucklidge JJ; Frampton CM; Gorman B; Boggis A
    Br J Psychiatry; 2014; 204():306-15. PubMed ID: 24482441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin-mineral treatment improves aggression and emotional regulation in children with ADHD: a fully blinded, randomized, placebo-controlled trial.
    Rucklidge JJ; Eggleston MJF; Johnstone JM; Darling K; Frampton CM
    J Child Psychol Psychiatry; 2018 Mar; 59(3):232-246. PubMed ID: 28967099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moderators of treatment response in adults with ADHD treated with a vitamin-mineral supplement.
    Rucklidge JJ; Johnstone J; Gorman B; Boggis A; Frampton CM
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Apr; 50():163-71. PubMed ID: 24374068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically Significant Symptom Reduction in Children with Attention-Deficit/Hyperactivity Disorder Treated with Micronutrients: An Open-Label Reversal Design Study.
    Gordon HA; Rucklidge JJ; Blampied NM; Johnstone JM
    J Child Adolesc Psychopharmacol; 2015 Dec; 25(10):783-98. PubMed ID: 26682999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micronutrients for Attention-Deficit/Hyperactivity Disorder in Youths: A Placebo-Controlled Randomized Clinical Trial.
    Johnstone JM; Hatsu I; Tost G; Srikanth P; Eiterman LP; Bruton AM; Ast HK; Robinette LM; Stern MM; Millington EG; Gracious BL; Hughes AJ; Leung BMY; Arnold LE
    J Am Acad Child Adolesc Psychiatry; 2022 May; 61(5):647-661. PubMed ID: 34303786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin-Mineral Treatment of ADHD in Adults.
    Rucklidge JJ; Frampton CM; Gorman B; Boggis A
    J Atten Disord; 2017 Apr; 21(6):522-532. PubMed ID: 24804687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial.
    Kean JD; Sarris J; Scholey A; Silberstein R; Downey LA; Stough C
    Psychopharmacology (Berl); 2017 Feb; 234(3):403-420. PubMed ID: 27921139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we predict treatment response in children with ADHD to a vitamin-mineral supplement? An investigation into pre-treatment nutrient serum levels, MTHFR status, clinical correlates and demographic variables.
    Rucklidge JJ; Eggleston MJF; Darling KA; Stevens AJ; Kennedy MA; Frampton CM
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():181-192. PubMed ID: 30217770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineral-Vitamin Treatment Associated with Remission in Attention-Deficit/Hyperactivity Disorder Symptoms and Related Problems: 1-Year Naturalistic Outcomes of a 10-Week Randomized Placebo-Controlled Trial.
    Darling KA; Eggleston MJF; Retallick-Brown H; Rucklidge JJ
    J Child Adolesc Psychopharmacol; 2019 Nov; 29(9):688-704. PubMed ID: 31343273
    [No Abstract]   [Full Text] [Related]  

  • 15. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.
    Cooper RE; Williams E; Seegobin S; Tye C; Kuntsi J; Asherson P
    Eur Neuropsychopharmacol; 2017 Aug; 27(8):795-808. PubMed ID: 28576350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
    Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
    J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
    Lee SI; Song DH; Shin DW; Kim JH; Lee YS; Hwang JW; Park TW; Yook KH; Lee JI; Bahn GH; Hirata Y; Goto T; Takita Y; Takahashi M; Lee S; Treuer T
    Asia Pac Psychiatry; 2014 Dec; 6(4):386-96. PubMed ID: 25345739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
    Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder.
    Manor I; Ben-Hayun R; Aharon-Peretz J; Salomy D; Weizman A; Daniely Y; Megiddo D; Newcorn JH; Biederman J; Adler LA
    J Clin Psychiatry; 2012 Dec; 73(12):1517-23. PubMed ID: 23290324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.